Skba Capital Management LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 106,600 shares of the biopharmaceutical company’s stock, valued at approximately $7,240,000.

Several other large investors have also recently made changes to their positions in the company. First PREMIER Bank raised its stake in shares of Gilead Sciences by 69.6% in the first quarter. First PREMIER Bank now owns 19,746 shares of the biopharmaceutical company’s stock valued at $1,341,000 after buying an additional 8,101 shares during the period. VNBTrust National Association purchased a new stake in shares of Gilead Sciences during the first quarter valued at approximately $212,000. Regentatlantic Capital LLC raised its stake in shares of Gilead Sciences by 21.7% in the first quarter. Regentatlantic Capital LLC now owns 52,014 shares of the biopharmaceutical company’s stock valued at $3,533,000 after buying an additional 9,280 shares during the period. Bank of Montreal Can raised its stake in shares of Gilead Sciences by 14.7% in the first quarter. Bank of Montreal Can now owns 2,526,453 shares of the biopharmaceutical company’s stock valued at $171,597,000 after buying an additional 324,187 shares during the period. Finally, E&G Advisors LP raised its stake in shares of Gilead Sciences by 0.4% in the first quarter. E&G Advisors LP now owns 25,694 shares of the biopharmaceutical company’s stock valued at $1,745,000 after buying an additional 99 shares during the period. 74.02% of the stock is currently owned by institutional investors and hedge funds.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down 0.31% during midday trading on Friday, hitting $73.79. 3,729,031 shares of the company’s stock traded hands. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $82.07. The company has a 50 day moving average price of $72.97 and a 200 day moving average price of $68.86. The firm has a market capitalization of $96.36 billion, a price-to-earnings ratio of 8.01 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. During the same period last year, the firm earned $3.08 EPS. The business’s quarterly revenue was down 8.2% compared to the same quarter last year. Equities analysts anticipate that Gilead Sciences, Inc. will post $8.74 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a $0.52 dividend. The ex-dividend date is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.82%. Gilead Sciences’s payout ratio is currently 22.58%.

TRADEMARK VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/08/27/skba-capital-management-llc-invests-7-24-million-in-gilead-sciences-inc-gild.html.

Several brokerages have recently commented on GILD. BidaskClub raised Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, August 2nd. BMO Capital Markets reissued an “outperform” rating and set a $82.00 price target (up previously from $72.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Deutsche Bank AG reissued a “buy” rating and set a $81.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Jefferies Group LLC reissued a “hold” rating and set a $83.00 price target on shares of Gilead Sciences in a research note on Thursday, July 27th. Finally, Cowen and Company reissued an “outperform” rating and set a $90.00 price target on shares of Gilead Sciences in a research note on Thursday, July 27th. Eleven analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and an average target price of $80.64.

In other news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the sale, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Gregg H. Alton sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the completion of the sale, the executive vice president now owns 137,488 shares in the company, valued at $10,174,112. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 206,666 shares of company stock worth $15,223,184. 1.30% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.